M&G plc’s Corcept Therapeutics CORT Stock Holding History

M&G plc’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-228,211	Closed	-$11.4M	–	445
2024 Q4	$11.4M	Sell	228,211 -14,690	-6%	-$770K	0.07%	183
2024 Q3	$11.2M	Buy	+242,901	New	+$8.63M	0.04%	198

Other funds holding CORT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

M&G plc's CORT Position: Q1 2025 in Review

M&G plc sold out of Corcept Therapeutics (CORT) in Q1 2025, closing a stake of 228,211 shares — an estimated $11.4M sold.

M&G plc first reported a position in CORT in Q3 2024 and held it in 2 quarters. The position peaked at $11.4M in Q4 2024. 422 funds tracked by Wall St. Rank hold CORT as of Q1 2025.

M&G plc reported no remaining Corcept Therapeutics position as of Q1 2025 after selling out during the quarter.
M&G plc sold 228,211 Corcept Therapeutics shares in Q1 2025, an estimated $11.4M.
M&G plc first reported a position in Corcept Therapeutics in Q3 2024 and held it in 2 quarters.
M&G plc's Corcept Therapeutics position peaked at $11.4M in Q4 2024.
422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2025.

Based on M&G plc's 13F filing for Q1 2025, filed 13 May 2025.